Skip header and navigation

Refine By

9 records – page 1 of 1.

[Diagnosis of primary of symptomatic forms of chronic daily headache].

https://arctichealth.org/en/permalink/ahliterature131542
Source
Zh Nevrol Psikhiatr Im S S Korsakova. 2011;111(4):82-4
Publication Type
Article
Date
2011

[Experience of using genfaxon for treating patients with relapsing-remitting multiple sclerosis in the Russian Federation].

https://arctichealth.org/en/permalink/ahliterature272370
Source
Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(8):39-45
Publication Type
Article
Date
2014
Author
K Z Bakhtiiarova
O V Bragina
Ia V Vlasov
I V Greshnova
E P Evdoshenko
E I Ivanishenkova
E I Kairbekova
E N Karnaukhova
N A Korotkevich
A V Leliukhina
I S Protasov
E V Rybina
A I Sazhnev
A A Skoromets
O A Soldatova
Iu V Trinitatskii
A S Fedianin
S N Chelnokova
V D Shabanova
R R Sharipova
E A Shchegol'kova
I A Iampol'skaia-Gosteva
Source
Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(8):39-45
Date
2014
Language
Russian
Publication Type
Article
Keywords
Adolescent
Adult
Biosimilar Pharmaceuticals - adverse effects - therapeutic use
Female
Humans
Interferon beta-1a - adverse effects - therapeutic use
Male
Middle Aged
Multiple Sclerosis, Relapsing-Remitting - drug therapy
Prospective Studies
Retrospective Studies
Russia
Treatment Outcome
Young Adult
Abstract
Multiple sclerosis (MS) is a chronic autoimmune demyelinating disorder of the central nervous system. Nowadays some disease-modifying drugs (DMD) in the Russian Federation (RF) are biosimilars. Their full spectrum of tolerability and efficacy is to be determined. Here we present results of two retrospective-prospective studies on efficacy and safety of a biosimilar interferon beta-1a (genfaxon) in treatment of MS in the RF.
determination of safety and efficacy profile of genfaxon in a routine neurological practice in the RF.
Trials were performed in 18 MS centers in the RF. A total of 649 patients aged from 18 to 68 years with the EDSS score no more than 6.0 were treated with genfaxon for 12 months. The first group was comprised of 'naïve' patients without previous history of DMD administration. There were patients in the second group which have already received some of DMD. Statistical analysis was performed with the help of significance criteria (?-square), t-criteria of Student for analysis of independent samplings.
There were no serious adverse events during the period of the study. "Naïve" patients had significantly lower number of adverse events, than patients with previous history of DMD usage. Efficacy results were comparable with results published for the Rebif.
Data, received from the studies show equal efficacy and tolerability of genfaxon compared with original DMD Rebif.
PubMed ID
25345629 View in PubMed
Less detail

[Medical and social aspects of childhood epilepsy].

https://arctichealth.org/en/permalink/ahliterature172275
Source
Zh Nevrol Psikhiatr Im S S Korsakova. 2005;105(9):64-5
Publication Type
Article
Date
2005

[Results of the XI All-Russian Congress of Neurologists and IV Congress of the National Associations Against Stroke].

https://arctichealth.org/en/permalink/ahliterature306789
Source
Zh Nevrol Psikhiatr Im S S Korsakova. 2020; 120(1):118-125
Publication Type
Congress
Author
A A Skoromets
T M Alekseeva
M P Topuzova
N E Ivanova
M L Pospelova
L V Lipatova
G N Bisaga
M Yu Efimova
Author Affiliation
Pavlov First Saint Petersburg State Medical University of the Ministry of Health of the Russian Federation, St. Petersburg, Russia.
Source
Zh Nevrol Psikhiatr Im S S Korsakova. 2020; 120(1):118-125
Language
Russian
Publication Type
Congress
Keywords
Humans
Neurologists
Neurology
Russia
Stroke
PubMed ID
32105279 View in PubMed
Less detail

[Study of prevalence and structure of cerebrovascular disorders in different regions of the USSR based on simultaneous epidemiological examinations].

https://arctichealth.org/en/permalink/ahliterature103944
Source
Zh Nevropatol Psikhiatr Im S S Korsakova. 1990;90(11):7-10
Publication Type
Article
Date
1990
Author
Iu Ia Varakin
M K Kipiani
N Z Molla-Zade
V E Smirnov
A A Skoromets
V A Sorokoumov
V L Feigin
V V Shprakh
E E Iusupov
N L Burdukovskaia
Source
Zh Nevropatol Psikhiatr Im S S Korsakova. 1990;90(11):7-10
Date
1990
Language
Russian
Publication Type
Article
Keywords
Adult
Cerebrovascular Disorders - epidemiology
Female
Humans
Male
Mass Screening - methods
Middle Aged
Prevalence
Russia - epidemiology
Transcaucasia - epidemiology
Urban Population
Abstract
The authors describe the data of the screenings of the representative random samples from the open male population aged 20 to 54 years, carried out in accordance with the common program in 6 cities of this country. The prevalence of definite cases of cerebrovascular diseases (CVD) ranged from 7.7% in Moscow to 12% in Irkutsk. As to the structure of cerebrovascular injuries, the initial manifestations of brain blood supply insufficiency accounted for 68%. The prevalence of CVD turned out to be the greatest in Western Siberia, the least in the European region. The transcaucasian republics occupy an intermediate position.
PubMed ID
1963985 View in PubMed
Less detail

[The 115-anniverssary of the department of neurology and neurosurgery of the Pavlov First Saint Petersburg State Medical University].

https://arctichealth.org/en/permalink/ahliterature272353
Source
Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(12):137-40
Publication Type
Article
Date
2015

[The basic factors affecting outcomes in strokes].

https://arctichealth.org/en/permalink/ahliterature216400
Source
Zh Nevrol Psikhiatr Im S S Korsakova. 1995;95(1):4-7
Publication Type
Article
Date
1995
Author
E I Gusev
B S Vilenskii
A A Skoromets
G S Burd
G M Semenova
V I Skvortsova
E A Shirokov
Source
Zh Nevrol Psikhiatr Im S S Korsakova. 1995;95(1):4-7
Date
1995
Language
Russian
Publication Type
Article
Keywords
Activities of Daily Living
Cerebrovascular Disorders - classification - mortality - therapy
Coma - mortality - therapy
First Aid
Humans
Intensive Care
Prognosis
Russia - epidemiology
Time Factors
Treatment Outcome
Urban Population - statistics & numerical data
Abstract
Outcomes in 1102 patients with 3 main types of stroke have been analysed to determine the significance of basic stroke outcome predictors. They are: type of the stroke, location of the focus, gravity of the patient's condition when the first aid is performed, spectrum of hospital facilities, diseases of the patient before and besides the stroke. A decrease of the mortality rate and optimal level of ADL score after stroke can be provided in cases when intensive care units-general hospitals are the first step of treatment.
PubMed ID
7778392 View in PubMed
Less detail

[The enhancement of prevention and treatment of the patients with the stroke in Saint-Petersburg].

https://arctichealth.org/en/permalink/ahliterature156611
Source
Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med. 2008 Mar-Apr;(2):27-30
Publication Type
Article
Author
V V Koval'chuk
A A Skoromets
E R Apkhanov
A Kh Umerov
E B Kuznetsova
M L Vysotskaia
E V Melikhova
Source
Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med. 2008 Mar-Apr;(2):27-30
Language
Russian
Publication Type
Article
Keywords
Adult
Age Distribution
Aged
Aged, 80 and over
Catchment Area (Health)
Female
Humans
Male
Middle Aged
Russia - epidemiology
Sex Distribution
Stroke - drug therapy - epidemiology - prevention & control
Abstract
The clinical epidemiological and medical organizational characteristics of strokes in 621 patients resident of Puschkinsky district of the City of Saint-Petersburg is presented. In the district, the corresponding morbidity and mortality rate is higher as compared with similar indicators in the Russian Federation and the international community. The comprehensive program of target actions on the prevention and treatment of the patients with the stroke is proposed both during acute and rehabilitation period.
PubMed ID
18567341 View in PubMed
Less detail

[The results of the multicenter pharmaco-epidemiological observational project on the use of mydocalm in the treatment of pain syndromes with the muscle spasm].

https://arctichealth.org/en/permalink/ahliterature272354
Source
Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(12):104-9
Publication Type
Article
Date
2015
Author
A A Skoromets
A B Gekht
D V Galanov
O A Danilenko
E R Barantsevich
A V Lebedeva
A N Belova
V V Shprakh
E I Bogdanov
S V Prokopenko
F A Khabirov
N N Spirin
V A Baliazin
V S Miakotnykh
L I Volkova
B G Gafurov
T S Mishchenko
Ch T Toktomushev
R K Shyralieva
S K Musaev
S G Guseinov
Source
Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(12):104-9
Date
2015
Language
Russian
Publication Type
Article
Keywords
Adult
Anti-Inflammatory Agents, Non-Steroidal - therapeutic use
Female
Humans
Male
Middle Aged
Muscle Relaxants, Central - adverse effects - therapeutic use
Pain - complications - drug therapy - epidemiology
Pharmacoepidemiology
Prospective Studies
Spasm - complications - drug therapy - epidemiology
Syndrome
Tolperisone - adverse effects - therapeutic use
Treatment Outcome
Abstract
The prospective multicenter open noncomparative pharmaco-epidemiological observational project on the use of mydocalm in real clinical practice has been completed in 2013. The project has been performed in 2090 clinical/rehabilitation settings in 284 cities of 13 countries using the results of 35,383 patients. The project aimed to assess the safety of treatment (percentage of patients with adverse-effects) and pain relieving efficacy as well as patient's satisfaction with the treatment. In total, 6603 (19%) adverse-effects were recorded. Their severity was evaluated as mild in 84,48%, no serious adverse-effects were noted. The high efficacy of mydocalm in the treatment of pain syndromes with the muscle spasm has been demonstrated. The high level of tolerability and absence of the clinically significant increase of adverse effects in the combination with nonsteroidal anti-inflammatory drugs have been confirmed.
PubMed ID
26978502 View in PubMed
Less detail

9 records – page 1 of 1.